跳至主要内容
临床试验/CTRI/2025/09/094475
CTRI/2025/09/094475尚未招募4 期

Randomized controlled trial comparing letrozole versus mifepristone for pretreatment in medical management of first trimester missed abortion

Dr Vandana Devi1 个研究点 分布在 1 个国家目标入组 82 人开始时间: 2025年9月20日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
82
试验地点
1
主要终点
9.To determine the efficacy of letrozole versus mifepristone as a pretreatment in management of first trimester missed abortion in terms of

研究概览

简要总结

Recent studies suggest that letrozole may enhance effectiveness of misoprostol in medical abortion the exploration of letrozole as a pretreatment agent before misoprostol administration present a promising alternative in medical management of first trimester missed abortion especially setting where mifepristone is contraindicated moreover letrozole can be cheaper than mifepristone

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 45.00 Year(s)(—)
性别
Female

入选标准

  • 1.Hemodynamically stable patient 2.Gestational age up to 12 complete weeks of gestation by LMP and missed.
  • abortion confirmed by following USG criteria [USG findings CRL more than 7mm and no heartbeat or mean sac diameter (MSD) more than 25 mm no embryo visualized] Hb 9 g/dl,.

排除标准

  • 1.Known hypersensitivity to letrozole or misoprostol, mifepristone 2.Known case of heart, liver, kidney disease and adrenal insufficiency 3.History of bleeding disorder or intake of anticoagulant drug 4.History of previous 2 LSCS or more, history of myomectomy or other uterine surgery 5.Diagnosed case of uterine fibroid, uterine anomalies.

结局指标

主要结局

9.To determine the efficacy of letrozole versus mifepristone as a pretreatment in management of first trimester missed abortion in terms of

时间窗: baseline follow by 2 week

Induction to expulsion interval

时间窗: baseline follow by 2 week

need for surgical interventions

时间窗: baseline follow by 2 week

次要结局

  • 1. To evaluate and compare the following complications and side effects in both the groups(a Abnormal uterine bleeding)

研究者

发起方
Dr Vandana Devi
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

DR VANDANA DEVI

Baba Saheb Ambedkar hospital Rohini new Delhi

研究点 (1)

Loading locations...

相似试验